Article
An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number.
Oncotarget - 7 Mar 2017
Szutowicz-Zielińska Ewa, Konopa Krzysztof, Kowalczyk Anna, Suszko-Każarnowicz Małgorzata, Duchnowska Renata, Szczęsna Aleksandra, Ratajska Magdalena, Sowa Aleksander, Limon Janusz, Biernat Wojciech, Burzykowski Tomasz, Jassem Jacek, Dziadziuszko Rafał
Abstract excerpt
BACKGROUND: First-line treatment with epidermal growth factor receptor (EGFR) inhibitors in NSCLC is effective in patients with activating EGFR mutations. The activity of erlotinib in patients harboring high EGFR gene copy number has been considered debatable. PATIENTS AND METHODS: A multicenter, open-label, single-arm phase II clinical trial was performed to test the efficacy of erlotinib in the first-line...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.